In a new study, the experimental cancer vaccine Provenge boosted the three-year survival of patients with advanced prostate cancer by 38 percent compared with a placebo. Researchers say the patients in the 512-subject study who received the drug, called Provenge, lived an average 4.1 months longer than those who did not receive the medication. One scientist on the study team said that if the drug becomes commercially available in the United States, he has "no doubt...it will replace...
Read moreA recent cervical cancer vaccine has been all over the news lately, both for its potential breakthrough impact on the lives of young... Read more »
Four of the seven currently available disease-modifying MS drugs are often referred to as “the interferons” - Avonex, Rebif, Betaseron,... Read more »
Often one is told they have decreased bone mineralization (osteoporosis or osteopenia) on their bone density (DXA) and are told to come... Read more »
Breastfeeding is one of the greatest gifts I have given to my two children and myself. It is a gift that has benefits far beyond... Read more »
According to a new study, the human papillomavirus (HPV) vaccine works for women aged 24 to 45 who aren't already infected by HPV, the virus that has... Read more »
The results of a new U.S. government study have found that the vaccine that protects against human papillomavirus (HPV), a cause of cervical cancer,... Read more »
Source: ADAM Encyclopedia
This test measures the amount of potassium in the blood. Potassium (K+) helps nerves and muscles communicate. It also helps move nutrients into cells... Read more »
Source: Medifocus Guidebook on: Complementary Cancer Therapies
In recent years, conventional medicine has made significant advances in the battle against cancer. The development of newer chemotherapeutic drugs... Read more »
Source: Medifocus Guidebook on: Carcinoid Tumor
Goals of Treatment of Carcinoid TumorsThe optimal management of patients with carcinoid tumors involves a multidisciplinary team of health care... Read more »